Durable CD8-mediated remission after brief anti-HIV-1 antibody treatment requires FcγR engagement
Proceedings of the National Academy of Sciences · 24.11.2026 · 123 (47)
DOI: 10.1073/pnas.2632384123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 17.11.2026. Verfasst von Stylianos Bournazos und 14 weiteren Autor:innen. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HHS | NIH, HHS | NIH | NIAID | Division of Intramural Research, amfAR, The Foundation for AIDS Research.
Abstract (Originalsprache)
Despite highly efficacious antiretroviral therapy (ART), durable ART-free remission remains a central objective of HIV-1 cure strategies. The randomized, placebo-controlled RIO trial recently demonstrated that long-acting broadly neutralizing anti-HIV-1 antibodies (bNAbs) can sustain prolonged virologic control after ART interruption, including control that persisted beyond the period of therapeutically relevant antibody concentrations, providing clinical evidence consistent with host-mediated suppression. However, the mechanisms underlying these “vaccinal” effects remain unresolved. Here, we establish Fcγ receptor (FcγR) engagement as an essential driver of multiyear remission after bNAb therapy in simian-human immunodeficiency virus (SHIV)-infected macaques. Brief therapy during acute infection with Fc domain variants of the bNAb 3BNC117, matched for antigen binding, neutralizing activity, and pharmacokinetics but differing in FcγR engagement, produced comparable early virologic control yet profoundly divergent long-term outcomes. Sustained CD8 T cell–dependent suppression lasting nearly 300 wk developed in every evaluable animal receiving the FcγR-engaging variant but arose in only one of eight recipients of the FcγR-null variant. FcγR-driven immunomodulation imprinted a CD8 T cell response characterized by enhanced antigen-specific effector function, early clonal focusing with sustained clonotype persistence, and distinct cellular-state transcriptional signatures. Our findings identify the Fc–FcγR axis as a critical determinant of the reliable induction of durable remission and provide a mechanistic framework for developing Fc-engineered bNAbs designed to enhance vaccinal immunity and advance antibody-based strategies with the potential to achieve functional cure.
Förderung
- HHS | NIH
- HHS | NIH | NIAID | Division of Intramural Research
- amfAR, The Foundation for AIDS Research
Zitieren
APA
Bournazos, S., Nishimura, Y., Grace, B. A. C., Niejadlik, E. G., Rogan, D. C., Meeks, T., Webber, J. D., Przygonska, P. A., Lehman, H., Minster, V. E., Jesteadt, E., Sadjadpour, R., Connors, M., Martin, M. A., & Ravetch, J. V. (2026). Durable CD8-mediated remission after brief anti-HIV-1 antibody treatment requires FcγR engagement. Proceedings of the National Academy of Sciences, 123(47). https://doi.org/10.1073/pnas.2632384123
Vancouver
Bournazos S, Nishimura Y, Grace BAC, Niejadlik EG, Rogan DC, Meeks T, et al. Durable CD8-mediated remission after brief anti-HIV-1 antibody treatment requires FcγR engagement. Proceedings of the National Academy of Sciences. 2026;123(47). doi:10.1073/pnas.2632384123
BibTeX
@article{Bournazos2026,
author = {Bournazos, Stylianos and Nishimura, Yoshiaki and Grace, Barbara Ann C. and Niejadlik, Emily G. and Rogan, Daniel C. and Meeks, Tyler and Webber, Jonathan D. and Przygonska, Paulina A. and Lehman, Hadrien and Minster, Veronica E. and Jesteadt, Eric and Sadjadpour, Reza and Connors, Mark and Martin, Malcolm A. and Ravetch, Jeffrey V.},
title = {Durable CD8-mediated remission after brief anti-HIV-1 antibody treatment requires FcγR engagement},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {47},
doi = {10.1073/pnas.2632384123}
}
EUVIMED